# Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

> **NCT05602727** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 99 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK-1942
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05602727
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-02
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-09-27
- **Target enrollment:** 99 (ACTUAL)
- **Why stopped:** Voluntarily terminated due to benefit/risk assessment
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602727, "Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05602727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*